Published online April 1, 2008
PEDIATRICS Vol. 121 No. 4 April 2008, pp. 703-710 (doi:10.1542/peds.2007-1130)

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Healy, C. M. Articles by Baker, C. J. Search for Related Content PubMed PubMed Citation Articles by Healy, C. M. Articles by Baker, C. J. Related Collections Infectious Disease & Immunity Related AAP Red Book topics: Yersinia enterocolitica and... Candidiasis (Moniliasis, Thrush) Social Bookmarking                         What's this?

ARTICLE

Fluconazole Prophylaxis in Extremely Low Birth Weight Neonates Reduces Invasive Candidiasis Mortality Rates Without Emergence of Fluconazole-Resistant Candida Species

C. Mary Healy, MD^a,b, Judith R. Campbell, MD^a,b, Elena Zaccaria, CIC^b and Carol J. Baker, MD^a,b,c

Departments of ^a Pediatrics
^c Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas
^b Woman's Hospital of Texas, Houston, Texas

OBJECTIVE. We evaluated the impact of fluconazole prophylaxis for extremely low birth weight infants on invasive candidiasis incidence, invasive candidiasis-related mortality rates, and fluconazole susceptibility of Candida isolates.

METHODS. Extremely low birth weight infants <5 days of age, except those with liver dysfunction, were eligible for fluconazole prophylaxis. NICU infants (all birth weights) with invasive candidiasis between April 2002 and March 2006 were compared with those with invasive candidiasis before fluconazole prophylaxis (2000–2001).

RESULTS. Twenty-two infants had invasive candidiasis (all candidemia) during fluconazole prophylaxis; before fluconazole prophylaxis, there were 19 cases (candidemia: 17 cases; meningitis: 2 cases). Invasive candidiasis incidence in NICU infants decreased from 0.6% (19 of 3012 infants) before fluconazole prophylaxis to 0.3% (22 of 6393 infants) in 2002–2006 and that in extremely low birth weight infants decreased 3.6-fold. No Candida-attributable deaths occurred during 2002–2006 fluconazole prophylaxis, compared with 4 (21%) before fluconazole prophylaxis. The onset of invasive candidiasis was later during 2002–2006 (23.5 vs 12 days), but risk factors were similar. The invasive candidiasis species distribution remained stable. Of 409 infants who received fluconazole prophylaxis, 119 (29%) received 42 days. Shorter fluconazole prophylaxis duration was related to intravenous access no longer being necessary in 242 cases (59%), noninvasive candidiasis-related death in 29 (7%), hospital transfer in 8 (2%), invasive candidiasis diagnosis in 8 (2%), and transient increase in serum transaminase levels in 4 (1%). One hundred twenty-seven infants (31%) who received fluconazole prophylaxis developed cholestasis during hospitalization, two thirds of whom had other predisposing conditions. On multivariate logistic regression necrotizing enterocolitis and increasing days of total parenteral nutrition, but not increasing number of doses on days of fluconazole, were significantly associated with the development of cholestasis.

CONCLUSION. During 4 years of fluconazole prophylaxis, the incidence of invasive candidiasis and invasive candidiasis-associated mortality rates in extremely low birth weight infants were reduced significantly, without the emergence of fluconazole-resistant Candida species.

---

Key Words: neonates • extremely low birth weight • Candida infection • fluconazole prophylaxis • resistance

Abbreviations: VLBW—very low birth weight • IC—invasive candidiasis • ELBW—extremely low birth weight • FP—fluconazole prophylaxis • CVC—central vascular catheter • BW—birth weight • TPN—total parenteral nutrition • MIC—minimal inhibitory concentration

---

Accepted Aug 29, 2007.

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. M. Varisco, K. W Benner, and P. Prabhakaran Neonatal Peritoneal Candidiasis Successfully Treated with Anidulafungin Add-On Therapy Ann. Pharmacother., November 1, 2009; 43(11): 1907 - 1910. [Abstract] [Full Text] [PDF]

				V. Vendettuoli, G. Vento, C. Tirone, B. Posteraro, and C. Romagnoli Antifungal Prophylaxis: Identification of Preterm Neonates at Highest Risk for Invasive Fungal Infection Pediatrics, February 1, 2009; 123(2): e368 - e369. [Full Text] [PDF]

				C. M. Healy Fungal Prophylaxis in the Neonatal Intensive Care Unit NeoReviews, December 1, 2008; 9(12): e562 - e570. [Abstract] [Full Text] [PDF]

				D. Kaufman Fluconazole Prophylaxis Decreases the Combined Outcome of Invasive Candida Infections or Mortality in Preterm Infants Pediatrics, November 1, 2008; 122(5): 1158 - 1159. [Full Text] [PDF]

				C. M. Healy and C. J. Baker Fluconazole Prophylaxis Decreases the Combined Outcome of Invasive Candida Infections or Mortality in Preterm Infants: In Reply Pediatrics, November 1, 2008; 122(5): 1159 - 1159. [Full Text] [PDF]

				D. Trofa, A. Gacser, and J. D. Nosanchuk Candida parapsilosis, an Emerging Fungal Pathogen Clin. Microbiol. Rev., October 1, 2008; 21(4): 606 - 625. [Abstract] [Full Text] [PDF]

				Fluconazole to Prevent Invasive Candidiasis in Tiny Preemies Journal Watch Infectious Diseases, April 23, 2008; 2008(423): 5 - 5. [Full Text]

				D. K. Benjamin Jr First, Do No Harm Pediatrics, April 1, 2008; 121(4): 831 - 832. [Full Text] [PDF]